Stock·NYSE·Healthcare
CVS Health Corp (CVS)
- Market cap
- $118.13B
- P/E
- 23.03
- Dividend yield
- 2.88%
- Street target
- $115.00median of 27 analysts
- 52-week range
- $69.51 $110.68
The short version
Where CVS stands today, in four lines, and what CleaRank Financial AI makes of it.
CVS at a glance
CVS Health Corp (CVS): Buy, 71/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($91.72 and $88.18).
- Earnings CVS beat estimates in 7 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $577.9M and bought $100K over the last 18 months.
- Valuation P/E of 23.0 against 31.9 for the Healthcare sector: a discount to peers (-28%).
Figures as of October 17, 2026.
CleaRank Financial AI
CVS Health Corp (CVS) carries a CleaRank rating of Buy and a model score of 71/100.
The analysts' outlook pushes the score up the most. 25 of 27 analysts rate the stock a buy, and the median target is 24.5% above the price. Momentum pulls the score down the most, with the MACD line negative. On trend, CVS trades 0.69% above its 50-day average of $91.72 and 4.74% above its 200-day average of $88.18. Over the past year, the price rose 13.51%.
Only on CleaRank
Figures we compute ourselves from CVS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $92.36 is 0.7% above the 50-day simple moving average of $91.72.Price above its 200-day average ›
The price is 4.7% above the 200-day simple moving average of $88.18.50-day average above the 200-day ›
The 50-day average ($91.72) is 4.0% above the 200-day average ($88.18), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 56% of its 52-week range, between $69.51 and $110.68.
CVS share price
Pick a period: each tab shows how far CVS has moved over it, to the last close.
Today's trading
Where CVS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 23.03 is 27.8% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 0.29 is 91.6% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $4.9B on revenue of $412.6B, a net margin of 1.2%.Beat estimates in most recent reports ›
CVS beat the EPS estimate in 7 of its last 8 reports.Pays a dividend ›
The trailing dividend yield is 2.88%, or $2.66 a share a year.
Key statistics
The headline figures for CVS.
As of October 17, 2026, CVS trades at $92.36, with a market value of $118.13B, a P/E ratio of 23.03 and a dividend yield of 2.88%.
What the numbers say
CleaRank Financial AI's reading of CVS's valuation, growth and risks.
CVS Health Corp (CVS) has a trailing P/E of 23.03, which is 27.8% below the Healthcare median of 31.9. The peer comparison on this page gives it a discount to peers. Its price-to-sales ratio of 0.29 is 91.5% below the sector median of 3.4.
Growth trails the sector: revenue grew 7.10% in the latest year, against a sector median of 8.1%. The business earns a net margin of 1.18% and an operating margin of 3.86% and a return on equity of 6.21%, below the sector median of 7.3%. Rounding out the fundamentals, CVS reports debt-to-equity of 0.96 and a trailing dividend yield of 2.88% ($2.66 a share a year).
CVS's latest report, dated August 5, 2026, beat the estimate by 39.46%: it earned $2.58 a share against an estimate of $1.85. Even so, the stock fell 2.93% in the next session.
CVS has beaten estimates in 7 of the last 8 reports, yet the share price moved lower in the next session after 4 of those 7 beats. The biggest earlier reaction followed the October 29, 2025 report: EPS beat the estimate by 17.65%, but the stock dropped 4.85%. Analysts expect EPS of $8.04 this fiscal year and $8.53 next, which implies 19.2% growth for the current year.
Over the last 30 days, the standard deviation of CVS's daily returns was 1.66%. The price is 16.55% below its 52-week high of $110.68. Over the last 18 months, insiders sold $577.9M of stock and bought $100K. Sales of this kind are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than open-market purchases.
CVS against the Healthcare sector
How CVS compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: CVS trades at a notable discount to sector peers (-28%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, CVS has gained 39.5% against a gain of 31.4% for XLV.
Performance against XLV
CVS and the Healthcare sector fund over the same days.
Revenue and earnings
How much CVS sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.8% in FY2025 to $402B, from $373B a year earlier.
Profit margin: The net margin was 0.4% in FY2025, down from 1.2% the year before.
Profitable: CVS earned $1.7B in FY2025.
Earnings reality check
Did CVS beat what analysts expected, and how did the stock react?
Earnings record: CVS beat the analyst estimate in 7 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $1.85 | $2.58 | +39.46% | -2.93% | -4.44% |
| May 6, 2026after close | $2.21 | $2.57 | +16.29% | +0.58% | +12.95% |
| Oct 29, 2025after close | $1.36 | $1.60 | +17.65% | -4.85% | -2.54% |
| Jul 31, 2025after close | $1.46 | $1.81 | +23.97% | +0.60% | +2.38% |
| May 1, 2025after close | $1.67 | $2.25 | +34.73% | -2.87% | -2.30% |
| Feb 12, 2025after close | $0.92 | $1.19 | +29.35% | +4.98% | +2.96% |
| Nov 6, 2024after close | $1.46 | $1.09 | -25.34% | -7.37% | -11.91% |
| Aug 7, 2024after close | $1.73 | $1.83 | +5.78% | -1.28% | -0.50% |
As of October 17, 2026, CVS has beaten the analyst EPS estimate in 7 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on August 5, 2026, came in 39.46% above the estimate and the stock moved -2.93% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 58.2, in neutral territory.RSI above 50 ›
An RSI of 58.2 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of CVS
The score, the reasoning behind it, and what could move the price next.
CVS Health Corp (CVS) is trading at $92.36, above both of its main moving averages. The price sits 0.69% above the 50-day average of $91.72 and 4.74% above the 200-day average of $88.18. The 50-day average is 4.02% above the 200-day, so the two averages point to an uptrend. Over the past year, the price is 32.87% above the 52-week low of $69.51 and 16.55% below the high of $110.68.
The short and long run point different ways: the price rose 0.70% over the past month, fell 14.06% over the past three months and rose 13.51% over the past year. The 14-day RSI of 58.2 is in the neutral zone, and the MACD line is negative.
Earnings beat ›
The August 5, 2026 report beat the EPS estimate by 39.46%, and the share price fell 2.93% in the first session after it.
Source: Earnings report, August 5, 2026
Rating reaffirmed ›
UBS kept its Buy rating on September 3, 2026.
Source: Analyst action, UBS, September 3, 2026
- Keep an eye on the two closest levels: the 52-week high at $110.68 sits above the price, and the 50-day SMA at $91.72 sits below it.
- The 14-day RSI stands at 58.2, in the neutral zone, and the MACD line is negative. Readings above 70 or below 30 would point to stretched momentum.
- After the August 5, 2026 report the share price fell 2.93% in the first session; CVS beat estimates in 7 of the last 8 reports.
The uptrend depends on CVS holding above its 50-day average of $91.72 and its 200-day average of $88.18. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the 50-day SMA at $91.72 is the first level it would reach.
The next level overhead for CVS is its 52-week high of $110.68.
Technical indicators
Momentum and trend for CVS, from its daily closes.
As of October 17, 2026, with CVS at $92.36, its 14-day RSI is 58.2 (neutral territory), its 50-day simple moving average is $91.72 and its 200-day is $88.18.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CVS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CVS's 1-year correlation of daily returns is +0.13 with S&P 500 (SPY), +0.06 with Nasdaq 100 (QQQ), -0.01 with Bitcoin (BTC) and -0.03 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
25 of 27 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $115.00 is 24.5% above the price.More buy ratings than three months ago ›
25 of 27 rate it a buy now, against 24 of 28 three months ago.
CVS Wall Street View
12-month price targets
The price, $92.36, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 3, 2026 | UBS | Maintains | Buy |
| Aug 19, 2026 | Argus Research | Maintains | Buy |
| Aug 12, 2026 | JP Morgan | Maintains | Overweight |
| Aug 6, 2026 | UBS | Maintains | Buy |
| Aug 6, 2026 | Evercore ISI Group | Maintains | Outperform |
| Aug 6, 2026 | Barclays | Maintains | Overweight |
As of October 17, 2026, 27 Wall Street analysts cover CVS: 25 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $103.00 to $145.00, with a median of $115.00, 24.5% above the price of $92.36.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CVS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CVS's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CVS tends to move, against the market and on its own.
The long record
CVS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.66% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 56.0%, from January 2022 to December 2024, regained by May 2026.Most 1-year holds ended higher ›
51% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $14,457, against $42,058 in the S&P 500 (SPY).
CVS Drawdowns & Recovery
As of October 17, 2026, CVS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -56.0% (January 2022 to December 2024); it regained that peak by May 2026, 17 months after the low, and 51% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CVS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CVS trailed the S&P 500 over this period: $14,457 against $42,058.
A $10,000 investment in CVS in October 2016 would be worth about $14,457 today with dividends reinvested, compared with about $42,058 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CVS, and which have not.
Strongest month, November: an average of +5.34%, up in 8 of 10 years.
Weakest month, February: an average of -4.04%, up in 3 of 10 years.
This month, October: has averaged -2.23%, up in 3 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CVS's strongest calendar month has been November (average +5.34%, up in 8 of 10 years) and its weakest February (average -4.04%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CVS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CVS today could grow to about $14,081 by 2036 in the base case, with a 90th-percentile outcome near $47,075 and a 10th-percentile outcome around $4,212. The simulation models price only; at today's 2.88% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CVS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $106 for CVS by 2030 in the base case, from $92.36 today (1.1x over 4 years). The 10th-percentile path ends near $49.37. These are outcomes of a Monte Carlo simulation run on CVS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $65.25 | $95.58 | $140 | |
| 2028 | $57.65 | $98.90 | $170 | |
| 2029 | $52.84 | $102 | $198 | |
| 2030 | $49.37 | $106 | $227 | |
| 2031 | $46.68 | $110 | $257 |
Method: a lognormal simulation of CVS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CVS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $100K on the open market and sold $577.9M.
As of October 17, 2026, CVS insiders reported 4 open-market sales worth $577.9M and 1 open-market purchase worth $100K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Larry Robbins
Director
|
Sell | 3.4M | $317.5M |
| May 14, 2026 | Fernando Aguirre
Director
|
Grant | 1.6K | $151.8K |
| May 14, 2026 | Jeffrey R M.d., Ph.d. Balser
Director
|
Grant | 2.1K | $199.9K |
| May 14, 2026 | C David Brown II
Director
|
Grant | 1.5K | $150.0K |
| May 14, 2026 | John Scott Kirby
Director
|
Grant | 1.4K | $140.6K |
| May 14, 2026 | Leslie V Norwalk
Director
|
Grant | 1.4K | $140.6K |
| May 14, 2026 | Guy P Sansone
Director
|
Grant | 1.4K | $140.6K |
| May 8, 2026 | Tilak Mandadi
Officer
|
Sell | 69.6K | $6.2M |
| Mar 31, 2026 | Heidi B Capozzi
Officer
|
Grant | 10.0K | $720.0K |
| Mar 31, 2026 | James David Clark
Officer
|
Grant | 11.1K | $799.9K |
| Mar 31, 2026 | Amy Compton-Phillips
Officer
|
Grant | 5.6K | $400.0K |
| Mar 31, 2026 | John David Joyner
Chief Executive Officer
|
Grant | 86.3K | $6.2M |
| Mar 31, 2026 | Samrat S Khichi
General Counsel
|
Grant | 12.5K | $900.0K |
| Mar 31, 2026 | Tilak Mandadi
Officer
|
Grant | 22.3K | $1.6M |
| Mar 31, 2026 | Steven H Nelson
Officer
|
Grant | 22.3K | $1.6M |
| Mar 31, 2026 | Brian Newman
Chief Financial Officer
|
Grant | 19.5K | $1.4M |
| Mar 31, 2026 | Prem S Shah
Officer
|
Grant | 25.1K | $1.8M |
| Mar 19, 2026 | John E Gallina
Director
|
Grant | 582 | $41.8K |
| Nov 20, 2025 | Fernando Aguirre
Director
|
Grant | 1.8K | $136.9K |
| Nov 20, 2025 | Jeffrey R M.d., Ph.d. Balser
Director
|
Grant | 1.8K | $135.0K |
| Nov 20, 2025 | C David Brown II
Director
|
Grant | 1.8K | $135.0K |
| Nov 20, 2025 | Anne A Finucane
Director
|
Grant | 591 | $44.9K |
| Nov 20, 2025 | John Scott Kirby
Director
|
Grant | 1.7K | $125.6K |
| Nov 20, 2025 | Leslie V Norwalk
Director
|
Grant | 1.7K | $125.6K |
| Nov 20, 2025 | Guy P Sansone
Director
|
Grant | 1.7K | $125.6K |
| Nov 20, 2025 | Douglas H Shulman
Director
|
Grant | 1.7K | $125.6K |
| Aug 20, 2025 | Anne A Finucane
Director
|
Sell | 7.5K | $532.7K |
| Jun 5, 2025 | Guy P Sansone
Director
|
Buy | 1.6K | $100.0K |
| May 30, 2025 | Amy Compton-Phillips
Officer
|
Grant | 53.1K | $3.4M |
| May 30, 2025 | Brian Newman
Chief Financial Officer
|
Grant | 21.9K | $1.4M |
| May 15, 2025 | Fernando Aguirre
Director
|
Grant | 2.3K | $136.8K |
| May 15, 2025 | Jeffrey R M.d., Ph.d. Balser
Director
|
Grant | 2.2K | $135.0K |
| May 15, 2025 | C David Brown II
Director
|
Grant | 2.2K | $135.0K |
| May 15, 2025 | Anne A Finucane
Director
|
Grant | 692 | $41.8K |
| May 15, 2025 | John Scott Kirby
Director
|
Grant | 2.8K | $167.4K |
| May 15, 2025 | Michael F Mahoney
Director
|
Grant | 144 | $8.7K |
| May 15, 2025 | Leslie V Norwalk
Director
|
Grant | 2.1K | $125.6K |
| May 15, 2025 | Guy P Sansone
Director
|
Grant | 2.1K | $125.6K |
| May 15, 2025 | Douglas H Shulman
Director
|
Grant | 2.1K | $125.6K |
| May 6, 2025 | Larry Robbins
Director
|
Sell | 3.8M | $253.7M |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.